University of Mississippi

eGrove
Faculty and Student Publications

Pharmacy, School of

12-1-2020

Clinical relevance of cancer stem cell chemotherapeutic assay for
recurrent ovarian cancer
Candace M. Howard
University of Mississippi Medical Center

Nadim Bou Zgheib
Marshall University

Stephen Bush
Charleston Area Medical Center

Timothy DeEulis
St. Mary's Medical Center, Huntington

Antonio Cortese
Università di Salerno

See next page for additional authors

Follow this and additional works at: https://egrove.olemiss.edu/pharmacy_facpubs
Part of the Pharmacy and Pharmaceutical Sciences Commons

Recommended Citation
Howard, C. M., Zgheib, N. B., Bush, S., DeEulis, T., Cortese, A., Mollo, A., Lirette, S. T., Denning, K., Valluri, J.,
& Claudio, P. P. (2020). Clinical relevance of cancer stem cell chemotherapeutic assay for recurrent
ovarian cancer. Translational Oncology, 13(12), 100860. https://doi.org/10.1016/j.tranon.2020.100860

This Article is brought to you for free and open access by the Pharmacy, School of at eGrove. It has been accepted
for inclusion in Faculty and Student Publications by an authorized administrator of eGrove. For more information,
please contact egrove@olemiss.edu.

Authors
Candace M. Howard, Nadim Bou Zgheib, Stephen Bush, Timothy DeEulis, Antonio Cortese, Antonio Mollo,
Seth T. Lirette, Krista Denning, Jagan Valluri, and Pier Paolo Claudio

This article is available at eGrove: https://egrove.olemiss.edu/pharmacy_facpubs/21

Translational Oncology 13 (2020) 100860

Contents lists available at ScienceDirect

Translational Oncology
journal homepage: www.elsevier.com/locate/tranon

Clinical relevance of cancer stem cell chemotherapeutic assay for recurrent
ovarian cancer☆
Candace M. Howard a, Nadim Bou Zgheib b, Stephen Bush II c, Timothy DeEulis d, Antonio Cortese e, Antonio Mollo f,
⁎
Seth T. Lirette g, Krista Denning h, Jagan Valluri i, Pier Paolo Claudio j,
a

Department of Radiology, University of Mississippi Medical Center, Jackson, MS, USA
Gynecologic Oncology, Edwards Comprehensive Cancer Center, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV, USA
Gynecologic Oncology, Charleston Area Medical Center Hospital, Charleston, WV, USA
d
Gynecologic Oncology, Women's Oncologic Palliative Medicine, St. Mary's Hospital, Huntington, WV, USA
e
Department of Medicine and Surgery, University of Salerno, Italy
f
Obstetric and Gynecologic Unit, Department of Medicine and Surgery, University of Salerno, Salerno, Italy
g
Department of Data Science, University of Mississippi Medical Center, Jackson, MS, USA
h
Department of Anatomy and Pathology, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV, USA
i
Department of Biological Sciences, Marshall University, Huntington, WV, USA
j
Department of BioMolecular Sciences, National Center for Natural Products Research, and Department of Radiation Oncology, University of Mississippi Medical Center Cancer
Institute, Jackson, MS, USA
b
c

A R T I C L E

I N F O

Article history:
Received 3 June 2020
Received in revised form 18 July 2020
Accepted 18 August 2020
Keywords:
Recurrent Ovarian Cancer
Cancer Stem Cells
Chemotherapeutic Drug Cytotoxicity Assay
ChemoID
Drug Response Assay

A B S T R A C T

Introduction: Disease recurrence and progression of ovarian cancer is common with the development of platinumresistant or refractory disease. This is due in large part to the presence of chemo-resistant cancer stem cells (CSCs)
that contribute to tumor propagation, maintenance, and treatment resistance. We developed a CSCs drug cytotoxicity
assay (ChemoID) to identify the most effective chemotherapy treatment from a panel of FDA approved chemotherapies.
Methods: Ascites and pleural ﬂuid samples were collected under physician order from 45 consecutive patients affected
by 3rd-5th relapsed ovarian cancer. Test results from the assay were used to treat patients with the highest cell kill
drugs, taking into consideration their health status and using dose reductions, as needed. A retrospective chart review
of CT and PET scans was used to determine patients' outcomes for tumor response, time to recurrence, progression-free
survival (PFS), and overall survival (OS).
Results: We observed that recurrent ovarian cancer patients treated with high-cell kill chemotherapy agents guided by
the CSCs drug response assay had an improvement in the median PFS corresponding to 5.4 months (3rd relapse),
3.6 months (4th relapse), and 3.9 months (5th relapse) when compared to historical data. Additionally, we observed
that ovarian cancer patients identiﬁed as non-responders by the CSC drug response assay had 30 times the hazard of
death compared to those women that were identiﬁed as responders with respective median survivals of 6 months vs.
13 months. We also found that ChemoID treated patients on average had an incremental cost-effectiveness ratio (ICER)
between -$18,421 and $7,241 per life-year saved (LYS).
Conclusions: This study demonstrated improved PFS and OS for recurrent ovarian cancer patients treated with assayguided chemotherapies while decreasing the cost of treatment.

Introduction
Cytoreductive surgery followed by platinum-based chemotherapy are
standard of care for new cases of epithelial ovarian cancer (EOC) [1]. Although this regimen is initially effective in a high percentage of cases,

unfortunately, most patients relapse. This is mostly attributed to the presence of ovarian cancer stem cells (CSCs), which are chemo-resistant and responsible for the recurrence of cancer [2]. CSCs account not only for the
primary tumor growth, the peritoneal spread and relapse of ovarian cancer,
but also for the development of chemoresistance, thus having profound

Abbreviations: rEOC, recurrent epithelial ovarian cancer; PFS, progression-free survival; OS, overall survival; CSCs, cancer stem cells; RT, radiation therapy.
☆ Keypoint: Cancer Stem Cell Chemotherapeutics Assay improves the outcome of recurrent ovarian cancer patients by guiding their chemotherapy treatment.
⁎ Corresponding author at: Department of BioMolecular Sciences, National Center for Natural Products Research, Department of Radiation Oncology, University of Mississippi, Jackson, MS
39126, USA.
E-mail address: pclaudio@olemiss.edu. (P.P. Claudio).
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to standardization [24]. Toxicity proﬁles are extensive for most chemotherapy drugs with no guarantee of success at the patient level. As such, there is
an urgent need for ways to tailor chemotherapy regimens to patients based
on their individual tumor characteristics.
We have developed a cytotoxicity assay (ChemoID), a CLIA (Clinical
Laboratory Improvement Amendments) and CAP (College of American Pathologists) certiﬁed test, performed by an independent Hospital Pathology
laboratory to help physicians' select appropriate chemotherapies for individual patients based on the cytotoxicity proﬁle of CSCs and bulk of
tumor cells response to FDA approved chemotherapies.
The drug response assay measures the effect of clinical doses of
standard-of-care chemotherapies on CSCs and bulk of tumor cells with a
prioritized list of effective and ineffective chemotherapies. The goal of the
assay is to ﬁnd the most efﬁcacious agents that would reduce CSC-burden
in ovarian cancer, thereby limiting metastatic and recurrent disease potential to help improve outcomes and to reduce health care costs. Previous economic analyses showed cost savings in cohorts of patients treated with
therapies guided by a cytotoxic assay [25,26], thus warranting an economic
analysis of the ChemoID assay based on patient clinical outcomes.
We report here for the ﬁrst time the clinical beneﬁt we observed from
the chart review of a cohort of consecutive recurrent ovarian cancer patients who were treated using the ChemoID drug response assay. The current analysis sought also to investigate the relative cost-effectiveness of
assay-guided treatment regimen relative to the assay-uninformed, empiric
standard of care, assuming the payer's perspective. Additionally, the survival analysis of the patients treated with assay-guided regimens was used
to inform the power analysis calculations for randomized multiinstitutional clinical trials that are currently being conducted in the USA.

implications for the treatment of this deadly disease [3]. Indeed, CSCs account for a very small subpopulation in the primary tumor that is enriched
in recurrent disease, both because of their expansion to fuel the relapse and
because of the possible selection of drug-resistant CSCs after the ﬁrst-line
treatment. Malignant ascites is common in advanced EOC, both at initial diagnosis and upon recurrence, and contain CSCs which can survive and proliferate even under non-adherent conditions, leading to self-organized
spheroids of ovarian cancer cells that, result in peritoneal seeding [4–7].
Recurrent EOC is associated with signiﬁcant mortality and a median
survival of only 12–24 months [8]. The combination of platinum drugs
with a taxane is the standard of care for systemic treatment of EOC after primary cytoreductive surgery [9]. However, this treatment results in response
rate (RR) of ~70% in patients with suboptimally debulked disease, and of
~80% in patients with optimal cytoreductive surgery [10,11]. Disease recurrence is common in these patients, and most of them eventually develop
platinum-resistant disease (deﬁned as disease recurring within 6 months
after the last receipt of platinum-based chemotherapy) [12,13].
RRs and duration of response to second-line chemotherapy for patients
with recurrent platinum-resistant disease are signiﬁcantly lower than those
with platinum-sensitive disease. In women with platinum-resistant disease,
RRs range from 10%–15%, and duration of response is typically
<6 months, with PFS (3–4 months), and OS (~12 months) to chemotherapeutic agents such as pegylated liposomal doxorubicin (PLD), topotecan,
taxanes, etoposide, and gemcitabine [14]. In comparison, the RRs are usually >30% and/or duration of response >8 months in women with
platinum-sensitive disease [15,16].
While treatment guidelines for the primary occurrence of advanced
stage EOC recommend numerous platinum-based combination therapies,
an even greater number of treatment regimens are recommended for recurrent disease. Nearly 10 different platinum-based therapies are recommended for treatment of patients experiencing recurrence following
>6 months from ﬁrst-line treatment (platinum-sensitive recurrent disease),
and over 20 different therapies (mostly single agents) for treatment of patients experiencing recurrence within 6 months following ﬁrst-line treatment (platinum-resistant recurrent disease) [17], with little to no
guidance on how to select among the treatment options. Thus, in the absence of speciﬁc directives beyond the primary setting, treatment choices
for recurrent EOC patients are made empirically [18]. Regimens to treat recurrent EOC are normally informed by responses to ﬁrst-line therapies and
vary signiﬁcantly; therefore, choice of which agent to use is usually based
on toxicity proﬁle, the previous toxicities experienced by the patient, and
patient preference. Several clinical trials, many supported by the National
Cancer Institute's consortium the Gynecologic Oncology Group (GOG),
have investigated chemotherapy drugs, regimens, and reductive surgery
methods in search of effective strategies to prevent EOC recurrence. Recently, the AURELIA, OCEANS, and GOG-0213 phase-3 randomized trials
have assessed combination therapy with a targeted agent such as
bevacizumab for recurrent platinum-resistant and –sensitive ovarian cancer
[19–23] and found that in patients receiving bevacizumab/chemotherapy,
the primary endpoint of PFS was signiﬁcantly prolonged (6.8 months versus 3.4 months, hazard ratio (HR) 0.48, 95% conﬁdence interval (CI)
0.38–0.60, p < 0.001) compared to patients treated with chemotherapy
alone. In these studies, the median overall survival was 16.6 months for
the bevacizumab/chemotherapy combination versus 13.3 months for chemotherapy alone; however, the difference was not statistically signiﬁcant
(HR 0.85, 95% CI, 0.66–1.08, p < 0.174).
Nonetheless, none of these trials have addressed or explored the idea of
reducing the burden of cancer stem cells in recurrent EOC to enable a
greater and more durable response to therapy. Despite results demonstrating treatment advances, regimens for platinum-resistant recurrent EOC are
unfortunately not curative. Thus, there is an urgent need for the development of alternative strategies given the poor response of platinumresistant recurrent ovarian epithelial malignant disease.
Individual patient responses to standardized treatments vary signiﬁcantly. Oncologists point to patient race/ethnicity, age, and comorbidities, as well as nuances in how EOC lesions are graded as challenges

Material and methods
Patients
We have retrospectively reviewed the charts of 45 consecutive female
18 years and older, clinically diagnosed with poor-prognosis recurrent
EOC (3rd–5th relapse), who were prospectively treated with the highest
cell kill drugs as identiﬁed by the ChemoID drug response assay, according
to their overall functional status and ability to tolerate the recommended
treatment and using dose reductions, as needed. Sample collections were
acquired from standard-of-care therapeutic paracentesis, or thoracentesis
to manage their symptoms after obtaining patients' written informed consent under the ethical standards of the Helsinki Declaration (1964,
amended most recently in 2008) of the World Medical Association. Any information, including radiological imaging, was blinded. Marshall University Institutional Review Board (IRB) has approved this research under
protocol #326290. Participants provided their written consent on an IRB
approved informed consent form to participate in this study after being educated about the research protocol. Ethics committees at Marshall University approved the consent procedure of the study. Fresh ﬂuid collections
were sent to the Pathology lab for conﬁrmation of diagnosis and a portion
of the biopsy specimen was sent for ChemoID drug response assay by physician order. Radiological data were collected at baseline before to ﬂuid collection and after chemotherapy with a computed tomography (CT) scan
and/or positron emission tomography (PET) with follow-up every 2–3 months. Repeated measures of drug response were not obtained, and
therefore each woman's data appears once. Supportive care was allowed
at the discretion of the treating physician. Response to treatment was
assessed by radiologic examination (CT scan as the primary imaging
method) and measurements using the RECIST 1.1 criteria.
ChemoID assay
Details regarding the CSCs cytotoxicity assay (ChemoID) procedure
have been described elsewhere [27–33]. In brief, primary cancer cell cultures were initiated from malignant cells present in the ascites or pleural aspirates. CSCs were enriched from the primary cancer cell cultures (bulk of
2
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Transplantation assay in immunodeﬁcient animals

tumor cells) as described previously [27–33] using a novel cell culture bioreactor with a membrane that allows for gas exchange. Cells were counted
and a range of 1 × 106–1 × 107 cells were cultured for 7–10 days. The cells
were maintained in RPMI 1640 medium in the rotating vessel at 25 rpm
with airﬂow constantly set at 20%, 5% CO2 at 37 °C. Cells were removed
and their viability and cell number were conﬁrmed. The cells were also incubated with ﬂorescent antibodies for phenotypic characterization.
For the ChemoID assay, the bulk of tumor cells and CSCs were counted
using trypan blue exclusion to determine cellular viability and cell number
before chemosensitivity testing. Percent of cell survival was assessed using
an MTT assay on 1 × 103 cells plated in 5 replicas into 96-well plates. An
equal number of the bulk of tumor cells and CSCs were seeded in 96-well
dishes and incubated at 37 °C for 24-h. Three concentrations of each chemotherapy treatment were prepared (dose 1: clinically equivalent dose to
serum CMax reported after 1 h from an infusion of a drug; dose 2: a double
dose of serum CMax; dose 3: 1/2 dose of serum CMax).
Clinical grade chemotherapy drugs were used in the assay provided by
the Hospital Pharmacy. The in vitro concentration equivalent to clinical
dose was calculated taking into account the molecular weight (MW) of
the drug, the average body surface area of female individuals, and the
stock molarity concentration of the clinical grade drugs. Each concentration
was added to ﬁve replicate wells on the microtiter plate. Additionally, three
replicate wells (control 1 = no treatment) and three replicate wells (control
2 = equal amount of solvent) were associated with each treatment. Only
clinically equivalent dose to serum CMax is reported by the clinical lab as
per CLIA laboratory guidelines for testing. The cells were challenged for a
1-h pulse with the panel of anticancer drugs (Table 1). MTT assay was performed 48-h following chemotherapy treatment to assess cell survival as
previously described [27,28,30,32–34]. Inhibition of bulk of tumor cells
and CSCs survival was measured for each concentration (average counts
in ﬁve replicates ± SE) of a given treatment (15–18 different treatments
per patient). Survival of tumor cells at each concentration was calculated
as compared to control-2 and overall percent of the bulk of tumor cells
and CSCs killed were calculated for each treatment as the primary measures
of potential therapy efﬁcacy.

Female nu/nu mice (nude; Jackson Labs) were used for in vivo
transplantation studies. Prepared cell suspensions were injected intraperitoneally using 1 mL syringes with a 25 G needle into 8-week-old
mice (n = 6 or 10). Tumors were assessed by necroscopy and sizes
were recorded by measuring the length and width of the tumors in
two dimensions using a caliper. The tumor volume (TV) was calculated using the formula volume = 1/2 × length (mm) × (width
[mm])2. Engraftment was determined according to progressive nodule
growth at the injection site. The tumorigenicity of ovarian cancer cells
was evaluated by measuring tumor-forming capacity following implantation of 1 × 101, 1 × 10 2, 1 × 10 3, and 1 × 104, 1 × 105, and
1 × 106 cells in the abdomen the nude mice. Tumor initiating properties of cultured CSCs were veriﬁed by injecting them in limited dilution in nude mice and observing after 30 days their tumor formation
capacity at necropsy. Fig. 1 illustrates the tumor-forming capacity of
1 × 10 2 ovarian CSCs enriched with the ChemoID culture method
compared to an equal number of CSCs sorted by a column (Milteny
Biotech, Auburn, CA) using a speciﬁc antibody following intraperitoneal injection in nude mice, compared to 1 × 106 bulk ovarian cancer
cells derived from a patient of our cohort. Column sorted and enriched
CSCs were also phenotypically characterized by ﬂow cytometry using
ﬂuorescent antibodies as previously described [27]. In brief, cells
were analyzed by the antigenic criteria using anti-CD44 (BD Bioscience, Sparks, MD), -CD117 (Milteny Biotech, Auburn, CA), and
-CD133/2 (prominin1) (Milteny Biotech, Auburn, CA). Brieﬂy, cells
were detached using 0.02% EDTA in PBS and pelleted (10 min at
1000 rpm), washed in 0.1% BSA in 1× PBS at 4C, and incubated in a
solution of 1 mg antibody + 9 mL 0.1% BSA in 1× PBS. Cells were
washed in the same solution once and were analyzed using a C6 Accuri
ﬂow cytometer (BD Biosciences, San Jose, CA).
Statistical analysis
Two different responder categories were deﬁned: the bulk of tumor responders were those women who received a treatment identiﬁed by the
drug response assay as 55% or above cell kill for the bulk of tumor and
CSC responders were those women who received a drug in which the test
identiﬁed as 40% or above cell kill of CSCs. These cell kill values were derived from previous research and validated in this sample via Youden indices. Summary statistics were calculated where appropriate and all relevant
graphs were constructed. Sensitivity, speciﬁcity, positive predictive value,
and negative predictive value were calculated according to standard approaches. Kaplan-Meier graphs were constructed and hazard ratios were
calculated from Cox models adjusted for the number of relapses and age.
Model assumptions were graphically checked and tested via Schoenfeld residuals and were found to be satisfactory. All statistical analyses were completed using Stata v15.1 (StataCorp LP, College Station, TX).

Table 1
List of single and combined chemotherapeutic agents used to treat recurrent epithelial ovarian carcinoma.
Regimen#

Single or combination drug(s) clinical dose tested

1
2
3
4
5
6
7
8
9
10
11
12

Liposomal Doxorubicin (30 or 60 mg/m2)
Docetaxel (75 mg/m2)
Paclitaxel (80 or 175 mg/m2)
Carboplatin (400 mg/m2)
Cisplatin (60 or 100 mg/m2)
Gemcitabine (800 or 1000 mg/m2)
Topotecan (1.25 mg/m2)
Etoposide (100 mg/m2)
Oxaliplatin (85 mg/m2)
Vinorelbine (30 mg/m2)
Vinblastine (3.75 mg/m2)
Carboplatin (400 mg/m2) +
Gemcitabine (800 or 1000 mg/m2)
Cisplatin (50 mg/m2) +
Gemcitabine (800 or 1000 mg/m2)
Carboplatin (400 mg/m2) +
Liposomal Doxorubicin (30 mg/m2)
Carboplatin (400 mg/m2) +
Paclitaxel (175 mg/m2)
Carboplatin (400 mg/m2) +
Docetaxel (75 mg/m2)
Gemcitabine (1000 mg/m2) +
Paclitaxel (80 or 175 mg/m2)
Gemcitabine (1000 mg/m2) +
Docetaxel (75 mg/m2)
Paclitaxel (175 mg/m2) +
Cisplatin (80 mg/m2)
Etoposide (100 mg/m2) +
Cisplatin (80 mg/m2)

13
14
15
16
17
18
19
20

Cost calculation
The major costs associated with the treatment of recurrent EOC are the
cost of the drug response assay, cost of surgery, cost of paracentesis/
thoracentesis, cost of chemotherapy, cost of adverse events and toxicities,
and cost of end of life care. It was assumed that all our patients incurred
the same cost per surgery, paracentesis/thoracentesis, and end of life care
and treatment of toxicities; therefore, we did not include these costs in
our analysis. For our analysis, we considered only the cost of chemotherapies. The main source for the cost data in this analysis reﬂects current
Medicare pricing.
Cost of chemotherapy
All patients in the current model were prospectively treated with a chemotherapy regimen appropriate to their ovarian cancer at the time of their
3
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Fig. 1. Limiting dilution transplantation assay in immunodeﬁcient animals. A-C) Necroscopic examination of intraperitoneal tumor nodules observed following injections of 1
× 102 CD44, CD133, or CD117 positive ovarian CSCs, respectively. Arrows point at tumor nodules D) Necroscopic examination of intraperitoneal tumor nodules observed
following injections of 1 × 102 ChemoID enriched ovarian CSCs. Arrows point at the several tumor nodules formed. E) Necroscopic examination of intraperitoneal tumor
nodules observed following injections of 1 × 106 bulk of tumor ovarian cancer cells. Only one tumor was observed in the control bulk of tumor injected mice.

Results

recurrence. The costs associated with 6 cycles of each chemotherapy regimen, as well as the associated administration costs (in the physician ofﬁce
setting), were estimated using the current Medicare physician fee schedule
for administration payments and drug pricing database for chemotherapy
agents [35,36]. Doses were calculated assuming a body surface area of
1.8 m2, serum creatinine of 0.9 mg/dL, the weight of 170 lb., the height
of 62 in., and the age of 63 years. To estimate the cost of the second-line
chemotherapy, the distribution of administered therapies in our cohort,
and the costs calculated for the historical cohort were used (Supplementary
Tables 1 and 2). Thus, the average cost of six cycles of salvage chemotherapy in the historical cohort was estimated at $20,311 in current dollars. The
cost of the second-line chemotherapy in the assay treated cohort was estimated by the average cost of all therapies in the highest category of assay
sensitivity for each patient; this cost was $20,528 in current dollars.

In vivo tumor formation by CSCs derived from primary recurrent ovarian cancer
The existence of CSCs and their ability to initiate a tumor was ﬁrst demonstrated by injecting in immunodeﬁcient animal populations of CSC
marker-positive cells using a limiting dilution assay (LDA). Populations of
CSC marker-positive cells that give rise to transplantable tumors, which histologically recapitulate the cellular heterogeneity of the parental tumors
can be classiﬁed as CSCs, whereas populations of CSC marker-negative
cells with no or limited tumor-propagating activity can be excluded from
the CSC candidates [38–40]. We measured tumor forming capacity of
CSCs enriched from patients' derived ovarian cancer primary cell lines
using our culture method and compared it to that of CSCs that were column
sorted cells using speciﬁc antibodies against CD133, CD44, and CD117
using an LDA assay. The tumor-initiating properties of patient-derived primary ovarian cancer cells was evaluated by measuring at necroscopy their
tumor-forming capacity following implantation of 1 × 101–1 × 106 cells in
the abdomen the nude mice after 30 days from an injection. Fig. 1 illustrates
the tumor-forming capacity of 1 × 102 ovarian CSCs enriched with the
ChemoID culture method compared to an equal number of CSCs sorted by
a column using a speciﬁc antibody following intraperitoneal injection in
nude mice, compared to 1 × 106 bulk ovarian cancer cells derived from a
patient of our cohort.

Cost-effectiveness and sensitivity analysis
The relative cost-effectiveness of the intervention is expressed by the incremental cost-effectiveness ratio per life-year saved (ICER/LYS), which is
the ratio of the difference in the average costs per patient to the difference
in the mean overall survivals. The standard threshold for a healthcare intervention to be deemed cost-effective is an expenditure of between $50,000
and $100,000 per additional year of life saved [37]. Keeping the costs for
surgery, chemoresponse assay, end of life care, and adverse event treatment
constant between our cohort and historical data, the model results are affected only by the cost of chemotherapies and by survival outcomes. To account for the uncertainty in the hazard ratio (HR) estimates associated with
the assay and its impact on the ICER/LYS, the range in the ICER/LYS was
estimated by 1000 bootstrap samples for the assay. Several stratiﬁed analyses for the reference model are also reported. To assess the sensitivity of
the model due to the cost of chemotherapy, the scenario when the oncologist chooses the least expensive treatment within the highest category of
sensitivity for each patient in the assay consistent cohort was also
investigated.

Assay guided clinical outcomes
Fresh tissue samples were prospectively collected from forty-ﬁve consecutive recurrent EOC patients (3rd–5th relapse) (Table 2) from a therapeutic peritoneal/pleural aspiration, as per physician order. The sample
was sent to the Hospital Pathology lab for conﬁrmation of diagnosis and,
at the same time, for the ChemoID CSC cytotoxicity assay. Patients were
treated with assay-guided chemotherapy according to their overall functional status and ability to tolerate the recommended treatment.
4
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Table 2
Patient characteristics (n = 45).
Characteristics
Age (median 60)
Range (28–77)
<50
50–59
60–69
≥70
Tumor relapse
3rd
4th
5th
ECOG
0
1
2
3
Tumor site
Ovarian
Peritoneal
Fallopian tube
Histology
Serous
Endometrioid
Clear cell
Mucinous
Unknown
Tumor grade
1
2
3
Stage
III
IV

No patients

%

6
14
19
6

(13.5)
(31)
(42)
(13.5)

31
6
8

(68.8)
(13.5)
(17.7)

22
15
5
3

(49)
(33)
(11)
(7)

39
5
1

(87)
(11)
(2)

40
3
1
1
0

(89)
(7)
(2)
(2)
(0)

0
3
42

(0)
(7)
(93)

40
5

(89)
(11)

Fig. 2. Quadrant diagram of the relationship between CSC assay results (%-cell kill
on the y-axis) and bulk tumor assay results (%-cell kill on the x-axis) characterized
by 6-months recurrence outcomes.

for both CSC and bulk tumor assays, who had a recurrence in <6 months.
We chose to analyze the recurrence outcome at 6 months because historical
data shows that patients affected by 3rd, 4th, and 5th relapse have a median
PFS of <6 months [8].
The CSC test demonstrated 97% sensitivity, 77% speciﬁcity, 91% positive predictive value (PPV), and 90% negative predictive value (NPG). The
bulk test demonstrated 84% sensitivity, 92% speciﬁcity, 96% PPV, and
71% NPG for the 6-month response.
Figs. 3 and 4 show Kaplan-Meier plots of progression-free and overall
survival across the study period stratiﬁed by dichotomized test results on
bulk of tumor test or CSC test, respectively. In the CSC model for overall survival (Fig. 3B), the ovarian cancer patients that the test identiﬁed as nonresponders had over 30 times the hazard of death compared to those
women that were identiﬁed by the test as responders (p < 0.001), with respective median survivals of 6 months vs. 13 months (p < 0.001). Likewise,
in the CSC model for progression-free survival (Fig. 4B), the ovarian cancer
patients that the test identiﬁed as non-responders had over 60 times the
hazard of progression compared to those women that were identiﬁed by
the test as responders (p < 0.001), with respective median survivals of
3 months vs. 9 months (p < 0.001). More modest but highly predictive hazards were observed based on the bulk of tumor models. Moreover, we observed that adding the bulk of tumor and CSC test response to a Cox
model containing only relapse number and age increased Harrell's C statistics from 0.63 to 0.79 for overall survival and from 0.62 to 0.84 for PFS.
Fig. 5 shows the baseline CT images of an ovarian cancer patient in her
third recurrence (Fig. 5A–C), the ChemoID drug response assay results
(Fig. 5D), and the subsequent CT images (Fig. 5E–G) following treatment
with ChemoID-guided therapy. Ascites was aspirated in November 2016
and a concomitant sample was sent to the pathology lab to conﬁrm the presence of malignant ovarian cancer cells and to the ChemoID lab for functional chemoresponse testing.

Two years after the last patient was treated, we performed a retrospective chart review of recurrent EOC patients treated using the test results of
the ChemoID assay. The mean age of the patients was 59.4 years (SD =
9.99). The majority of the women (31) were on their 3rd relapse (69%),
while 6 (13%) were on their 4th, and 8 (18%) were on their 5th relapse.
The CSC cytotoxicity assay identiﬁed 28 (62%) women as expected responders based upon bulk tumor and 34 (76%) as expected responders
based upon CSCs test. Historical data reports that patients affected by 3rd,
4th, and 5th relapse have a median PFS of 5.6, 4.4, and 4.1 months, respectively [8]. The median PFS observed in our recurrent patients treated with
sensitive drugs as indicated by the CSC cytotoxicity assay for 3rd, 4th, and
5th relapse was 11, 8, and 8 months, respectively (Table 3). This potentially
demonstrates a marked advantage of treating patients with assay-guided
therapy.
Fig. 2 illustrates the relationship between the CSC assay results (%-cell
kill on the y-axis) and bulk tumor assay results (%-cell kill on the x-axis)
characterized by recurrence outcomes at 6 month, with blue solid circles
representing treatment responders (non-recurrence at 6 months) and red
open circles representing patients with recurrence within 6 months from
treatment start. Referent lines are drawn at thresholds of 40% for CSC,
and 55% cell kill for the bulk of tumor. In the upper-right quadrant are represented patients treated with high-cell kill chemotherapy for both CSC and
bulk tumor assays, who were non-recurrent at 6 months. In the lower-left
quadrant are represented patients treated with low-cell kill chemotherapy

Pattern of assay response
Fig. 5 shows in the baseline CT imaging the presence of large ascites
(panel A), ovarian mass measuring 9.3 × 5.4 cm (panel B), and peritoneal
carcinomatosis measuring 3.5 × 5.1 cm (panel C). Fig. 5D shows the
ChemoID test results with several high suppression chemotherapy drugs.
Based on the patient clinical status (kidney disorder) and prior use of chemotherapy regimens, the patient was treated with a full course of single
chemotherapy agent (Doxorubicin) that showed a high percentage of cell
kill for both Bulk of Tumor (75.2% cell kill) and CSC (66.4% cell kill) by
the ChemoID assay. Other high cell kill drugs indicated by the assay were
not administered due their known side effects (kidney toxicity) which
were contraindicated by the speciﬁc health status of the patient.

Table 3
Comparison of historical median PFS and ChemoID-guided treated poor prognosis
ovarian cancer patients.
Relapse

Historical
Median PFS (months)

ChemoID
Median PFS (months)

Difference
Median PFS (months)

3rd
4th
5th

5.6
4.4
4.1

11.0 (8.5–12.0)
8.0 (7.0-NA)
8.0 (2.0-NA)

5.4
3.6
3.9
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Fig. 3. Kaplan-Meier plots of overall survival across the study period. Overall survival is shown stratiﬁed by dichotomized test results for (A) bulk test >55% cell kill responder or <55% cell kill – non-responder and (B) CSC test >40% cell kill - responder or <40% cell kill – non-responder; Hazard ratios are from Cox proportional
hazard models adjusting for number of previous relapses and age.

study, the reference model yielded an ICER of $860–$32,473, $1,100–
$48,890, and $0–$46,154 per LYS of 3rd, 4th, and 5th relapse patients, respectively (Table 6). We also found that ChemoID treated patients on average had an incremental cost-effectiveness ratio (ICER) between -$18,421
and $7,241 per life-year saved (LYS).
Results for the model using the least expensive chemotherapy within
the patient's highest category of sensitivity in the assay consistent cohort
showed that the range in the ICER/LYS estimated by 1000 bootstrap samples for the assay was -$5,590 (Supplementary Table 4).
When choosing the least expensive therapy within the test three highest
category of sensitivity, the average cost saving of six cycles of chemotherapy becomes $7,955 in the assay consistent cohort vs. historical control (p
< 0.001). This change alone in the model makes the chemoresponse
assay a positively dominant intervention that greatly changes the health
care cost.

Images in February of 2017 showed a dramatic reduction of ascites
(panel E), smaller ovarian mass measuring 5.8 × 3 cm (panel F), and reduction in peritoneal carcinomatosis measuring 3.4 × 3 cm (panel G).
Assay guided cost of treatment
To better understand the health care beneﬁt and the economical impact
of the use of the drug response assay, we compared the health beneﬁt observed and the cost of therapies used in our patients' cohort to the historical
data of patients treated empirically with chemotherapies, similarly to previously published investigations [26].
The mean cost of therapies administered to the 45 patients was $20,311
(Table 4). If the therapy with the minimum cost from the top three
ChemoID recommended therapies was administered, the average patient
would have saved $7,956/regimen. This difference was highly statistically
supported (p < 0.001).
We also compared the cost of PARPi (4 cycles) or Avastin therapies (4–22 cycles) (Supplementary Table 3) to 4 cycles of the administered drugs,
ChemoID's ﬁrst three recommendations, and the therapy with the minimum cost of the ﬁrst three choices (Table 5). Cost savings ranged from a
minimum of $31,689 to $273,644 (all p < 0.001). Interestingly, of the 45
patients, 33 (73%) could have received therapy either as effective or
more effective than the administered therapy for a reduction of the cost.
Table 6 illustrates the incremental cost-effectiveness ratio per life-year
saved (ICER/LYS), which is the ratio of the difference in the average costs
per patient to the difference in the mean overall survival. For the ChemoID

Discussion
This study for the ﬁrst time shows the utility of a new cancer stem cell
cytotoxicity assay for the management of poor prognosis recurrent ovarian
cancer patients. The current study also served to inform the power calculations for an ongoing larger follow-up randomized clinical trial on the use of
the CSCs assay to guide individualized chemotherapy choices and to improve recurrent ovarian cancer patient outcomes. The test is a functional
assay that uses patient's live tumor cells and CSCs isolated by tumor biopsies or malignant ﬂuid aspirates (peritoneal and/or pleural ﬂuid) to indicate

Fig. 4. Kaplan-Meier plots of progression-free survival across the study period. Progression -free survival is shown stratiﬁed by dichotomized test results for (A) bulk test
>55% cell kill - responder or <55% cell kill – non-responder and (B) CSC test >40% cell kill - responder or <40% cell kill – non-responder; Hazard ratios are from Cox
proportional hazard models adjusting for number of previous relapses and age.
6
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Fig. 5. CT Images and comparative analysis of ChemoID test results on Bulk of Tumor and Cancer StemCells of a patient affected by third recurrence of an ovarian cancer. A)
Baseline CT images show presence of large amount of ascites in December of 2016, with B) ovarian mass measuring 9.3 × 5.4 cm, and C) peritoneal carcinomatosis
measuring 3.5 × 5.1 cm. D) Comparative ChemoID analysis on Bulk of Tumor and Cancer Stem Cells obtained from fresh ascites aspirate. E) Control CT images in
November of 2017 following a Doxorubicin regimen showing regression of ascites, F) smaller ovarian mass measuring 5.8 × 3 cm, and G) smaller peritoneal
carcinomatosis measuring 3.4 × 3 cm.

which chemotherapy agent (or “combinations”) are more effective.
Targeting of CSCs alongside the bulk of other cancer cells is a new paradigm
in cancer treatment [41].
The current study evaluated the correlation of CSCs and bulk of tumor
cells chemoresponse assay results of recurrent EOC patients to treatment

outcomes independently of other biomarkers. All patients were treated
with a chemotherapy regimen that was chosen among those with the
highest cell kill guided by the CSCs drug response assay, taking into consideration their health status and using dose reductions, as needed. CT and
PET scans were used to prospectively monitor patients for tumor response,

Table 4
Cost comparison of administered drugs vs. ChemoID recommended drugs.
Actual drug cost

Vs. cost of ChemoID 1st choice

Vs. cost of ChemoID 2nd choice

Vs. cost of ChemoID 3rd choice

Vs. min of ChemoID ﬁrst three choices

$20,311.11

$18,356.56
(−$1,955.56)
p = 0.121

$18,533.33
(−$1,777.78)
p = 0.159

$17,555.56
(−$2,755.56)
p = 0.029

$12,355.56
(−$7955.56)
p < 0.001
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Table 5
Cost comparison of ChemoID recommended drugs vs. PARP Inhibitor (PARPi) or Bevacizumab (Avastin).

Actual drug cost
Vs. cost of ChemoID 1st choice
Vs. cost of ChemoID 2nd choice
Vs. cost of ChemoID 3rd choice
Vs. min of ChemoID First three choices

Vs. PARPi
(4 cycles)
$72,000

Vs. Avastin
(4 cycles)
$52,000

Vs. Avastin
(22 cycles)
$286,000

−$51,689
p < 0.001
−$53,644
p < 0.001
−$53,467
p < 0.001
−$54,444
p < 0.001
−$59,644
p < 0.001

−$31,689
p < 0.001
−$33,644
p < 0.001
−$33,467
p < 0.001
−$34,444
p < 0.001
−$39,644
p < 0.001

−$265,689
p < 0.001
−$267,644
p < 0.001
−$267,467
p < 0.001
−$268,444
p < 0.001
−$273,644
p < 0.001

sensitive therapies [46–50]. An analysis of survival from patients cohorts
in the control arm of phase-III randomized clinical trials indicated that
the various treatment regimens had similar efﬁcacy when therapies were
randomly assigned [50]. Therefore, in the comparative analysis, even
though therapies from the same set of approved and recommended treatment options were administered to participants, patients whose treatment
was assay-informed had improved survival when compared to patients
whose treatment was randomly assigned.
In our study, the ChemoID cytotoxicity assay identiﬁed highsuppression drugs against CSCs and the bulk of tumor cells contributing
to a durable clinical response in a statistically signiﬁcant manner. This
study reveals that patients who were treated with a chemotherapysensitive regimen against CSCs had an improvement in their time to progression and overall survival compared to patients who could not receive
assay sensitive regimens. In the CSC model for overall survival (Fig. 3B),
the ovarian cancer patients that assay identiﬁed as non-responders had
over 30 times the hazard of death compared to those women that were
identiﬁed by the assay as responders (p < 0.001), with respective median
survivals of 6 months vs. 13 months (p < 0.001). In the CSC model for
progression-free survival (Fig. 4B), ovarian cancer patients that the assay
identiﬁed as non-responders had over 60 times the hazard of progression
compared to those women that were identiﬁed by the assay as responders
(p < 0.001), with respective median survivals of 3 months vs. 9 months
(p < 0.001). More modest but highly predictive hazards were observed
based on the bulk of tumor models, demonstrating the superiority of prediction based on the CSCs model. Moreover, we observed that adding the bulk
tumor and CSC assay response to a Cox model containing only relapse number and women age increased Harrell's C statistics from 0.63 to 0.79 for
overall survival and from 0.62 to 0.84 for PFS. Overall, this data demonstrates the importance of determining the response of CSCs to chemotherapy and their role in patients' tumor response following chemotherapy.
This method of determining the response of CSCs to available FDA approved chemotherapies for the treatment of ovarian cancer, as well as
other cancers, may provide critical information about an individual
patient's likelihood to achieve a durable tumor response before
implementing the patient's treatment plan.
Although this study was conducted on a limited cohort of consecutive
patients affected by poor prognosis EOC, results indicate that a drug cytotoxicity assay that targets CSCs may be a useful tool for optimizing treatment selection when ﬁrst-line therapy fails, and when there are multiple
clinically-acceptable and -equivalent treatments available. These results

time to recurrence, progression-free survival (PFS), and overall survival
(OS). This is the ﬁrst-in-human case study to demonstrate that prospective
use of the CSCs drug response assay to select treatment for 45 patients affected by poor prognosis (3rd–5th relapse) recurrent ovarian cancer resulted in signiﬁcantly better PFS (median PFS of 11 months – 3rd relapse;
8 months – 4th relapse; and 8 months -5th relapse, respectively), compared
to historical data (5.6 months – 3rd relapse; 4.4 months – 4th relapse; and
4.1 months -5th relapse, respectively) (Table 3). We observed that in the
CSC model, the ovarian cancer patients that assay identiﬁed as nonresponders had over 30 times the hazard of death compared to those
women that were identiﬁed by the assay as responders (p < 0.001) with respective median survivals of 6 months vs. 13 months (p < 0.001) (Fig. 3).
Medical management of newly diagnosed epithelial ovarian carcinoma
(EOC) is typically a multimodal treatment plan constituted by surgical resection (when possible), followed by platinum-based chemotherapy [11].
Disease recurrence is common in these patients, and most of them eventually develop the platinum-resistant disease (deﬁned as disease recurring
within 6 months after the last receipt of platinum-based chemotherapy)
[12,13]. Recurrent EOC is associated with signiﬁcant mortality and a median survival of only 12–24 months that becomes progressively worse
with each additional recurrence [8]. Regimens to treat recurrent EOC are
normally informed by responses to ﬁrst-line therapies and vary signiﬁcantly; therefore, choice of which agent to use is usually based on toxicity
proﬁle, the previous toxicities experienced by the patient, and patient preference (3). Additionally, the aggressiveness of recurrent EOC is mostly attributed to the presence of ovarian cancer stem cells (CSCs), which are
chemo-resistant and responsible for the recurrence of cancer [42–45]. Individual patient responses to standardized treatments greatly vary and unfortunately, toxicity proﬁles are extensive for most chemotherapy drugs with
no guarantee of success at the patient level. As such, there is an urgent
need for ways to tailor chemotherapy regimens based on patients' individual tumor proﬁles to identify treatments that may lead to improvement in
PFS and OS.
Prospective and retrospective investigations conducted in the past years
have shown that in this era of personalized medicine, patients with recurrent ovarian cancer deserve better than the 25% response rate that is associated with drugs selected based on clinical information alone [46].
Previous studies, which were conducted using cytotoxicity assays against
the bulk of tumor only reported improved clinical outcomes for ovarian
cancer patients treated with sensitive chemotherapies as indicated by a
chemoresponse assay, compared with those patients treated with non-

Table 6
ICER/LYS Comparison of ChemoID recommended drugs for 3rd–5th relapse of recurrent EOC.

3rd relapse- average cost per patient
Median OS
4th relapse - average cost per patient
Median OS
5th relapse - average cost per patient
Median OS

Historical median PFS

Assay-guided cohort

ICER/LYS (range)

~$20,000–$35,000
5.6 months
$20,000–$35,000
4.4 months
~$20,000–$35,000
4.1 months

$20,387
11 months
$20,333
8 months
$20,000
8 months

$860–(−$32,473)
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chemotherapies against CSCs as indicated by the assay. More importantly,
the prediction of tumor responses to chemotherapy treatment in vitro was
directly associated with the OS and PFS of the treated patients. Interestingly, the data also suggests that the CSCs assay may identify alternate
treatments when tested in vitro that may be more effective in the subset
of patients whose tumors have relapsed and that have been classiﬁed clinically non-responsive to platinum agents. Together, this information suggests that the CSCs drug response assay has the potential to help to guide
individualized chemotherapy choices to beneﬁt patients by allowing the
physician to consider alternate regimens earlier in the treatment plan for
improving outcomes in recurrent ovarian cancer.

further suggest that the CSCs drug response assays may provide more treatment options for improved outcomes than currently achieved by empiric
population-based treatment in recurrent ovarian cancer. This concept is especially valuable and important with emerging value-based healthcare
models where outcomes-based contracts linked to payment for the indication of speciﬁc anticancer-drug prices raise concerns about the accessibility
and affordability for treatment of recurrent EOC patients. The power of precision medicine lies in its ability to guide health care decisions toward the
most effective treatment for a given patient, and thus, improve care quality
while reducing the use of ineffective therapies. In a recent retrospective
study involving metastatic cancer patients, researchers at the University
of Utah compared data from patients who received precision medicine
targeted therapy with data from patients who received standard chemotherapy or best supportive care [51]. It was observed that patients receiving
targeted treatment after precision oncology had doubled median overall
survival compared to patients receiving chemotherapy or supportive care.
Moreover, it was found that the average costs per week over the study period were almost half for patients receiving targeted therapy compared to
those receiving chemotherapy or supportive care indicating that precision
health and directed therapies have the potential to lower health care costs.
The current study compares the cost of treatment decisions that adhere
to chemo response assay results at the time of second-line therapy in patients with recurrent EOC with those that are made empirically, in the absence of chemoresponse testing, such as the historical control.
The cost-effective beneﬁt of a healthcare intervention such as a drug response assay is realized if the comprehensive cost of its use is less than
$100,000 per additional life-year saved [37]. In the current study, the use
of and adherence to chemoresponse assay results yield an ICER of $5,200
per additional life-year saved, suggesting that the assay intervention is
cost-effective even at a conservative $50,000 threshold. Furthermore, in
analyses of patients with an assay-sensitive result for at least one therapy,
the ICER dropped to -$5,590 per LYS in our cohort of platinum-resistant patients, where the need for decision support tools is greater due to poorer
prognosis than platinum-sensitive patients. While the current study examines cost-effectiveness in the recurrent EOC setting, future studies are
planned which will evaluate the cost-effectiveness of this chemoresponse
assay across the entire treatment duration of patients with advanced EOC,
accounting for its inﬂuence in both the primary and recurrent settings. Additionally, the use of a chemoresponse assay in making treatment decisions
may potentially reduce toxicities and their associated costs, as well as improve the patients' overall quality of life, by reducing the number of ineffective treatment rounds. Therefore, healthcare cost-effectiveness of the assay
may be further enhanced when accounting for these differences.
More clinical studies with a larger number of patients are needed to determine the clinical and economic implications of the CSCs cytotoxicity
assay. Although the current study represents a small sample cohort and
lacks randomization, nevertheless our results clearly showed that women
affected by poor-prognosis ovarian cancer treated with assay-guided regimens against CSCs had an improvement in their time to progression and
overall survival compared to patients treated empirically. Our study provides proof of concept for CSCs drug response assay in personalizing treatment strategies to increase survival time for recurrent EOC patients and was
useful in developing a larger multi-center randomized trial on the use of
this assay to guide therapy in recurrent ovarian cancer. We are conducting
a multi-institutional prospectively treated, randomized, blinded, controlled
trial on the use of the CSC cytotoxicity assay to guide therapy vs. physician's
choice chemotherapy in patients with platinum-resistant recurrent ovarian
cancer (NCT03949283), with the intent to determine the clinical impact of
CSC assay-directed therapy for recurrent ovarian cancer.
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